Will a gene therapy that edits multiple genes using CRISPR be approved by the FDA before 2030?
Santé et médecineOne-Off3a
Manifold MarketsSans KYCDonnées de résolution vérifiéesAssez bien calibréPrévision communautaire actuelle
Oui 78.9%
Oui 78.9%Prévisionnistes
29
Type de question
binary
Méthodologie
Play-money forecasting platform
Type de source
Prévision
Données du marché
Mis à jour il y a 1 heure
En retard26 janv. 24, 00:13 UTC1 janv. 30, 07:59 UTC
Tendances
Règles
In late 2023 the United States Food and Drug Administration (FDA) approved Casgevy, the first ever CRISPR-based gene therapy.
- Casgevy is a gene therapy for sickle cell disease, which is a hereditary disease caused by a mutation in a single gene (i.e. it’s monogenic).
- To count as a YES, a “gene therapy that edits multiple genes using CRISPR” should modify two or more genes in a patient’s genome by using some version of CRISPR (e.g. Cas9, an alternative protein).
- The gene therapy must be for humans.
- Will the FDA approve a multigenic gene therapy using CRISPR technology before 2030?
